Merck & Co., Inc. MRK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Key opinion leaders (KOLs) interviewed by GlobalData referred to oral GLP-1R agonists as “a very interesting evolution,” mainly referring to orforglipron. A European KOL mentioned that “for oral, I am ...

Pope Francis was joined by more than 10,000 people for a youth festival held at Sir John Guise Stadium in Port Moresby on the final day of his apostolic visit to Papua New Guinea (PNG), reminding ...

The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

The New York Knicks hope that the roster they have constructed this offseason will be enough to overtake the Boston Celtics and emerge atop the Eastern Conference. However, they have a lot of ...

Keytruda, a PD-1 checkpoint inhibitor, generated $25bn last year, as per MSD’s financials. This revenue flow is expected to continue growing with GlobalData predicting that the blockbuster will pull ...